Fexuprazan offers quicker symptom relief in patients with severe laryngopharyngeal reflux disease compared to Esomeprazole, without serious side effects.
In a recent investigation, Fexuprazan (a novel potent potassium-competitive acid blocker) accelerated symptom improvement for patients with severe laryngopharyngeal reflux disease (LPRD) compared to traditional proton pump inhibitors (PPIs) like Esomeprazole. This study published in the “European Archives of Oto-Rhino-Laryngology” aimed to compare Fexuprazan's efficacy and safety with that of Esomeprazole in LPRD.
In this prospective, double-blinded, multicenter, randomized clinical trial, patients with a reflux symptom index (RSI) of 13 or higher and a reflux finding score (RFS) of 7 or higher were enrolled. Volunteers were randomly allocated to get either Fexuprazan (40 mg) or Esomeprazole (40 mg) daily for eight weeks. Outcomes measured included mean change, change rate, and valid rates in RSI, RFS, and related questionnaires, along with adverse events. Overall,136 subjects finished the study (68 in each group).
Both treatments markedly improved all parameters at 4 and 8 weeks, with no major differences between the groups overall. However, patients with severe symptoms (RSI ≥ 18) experienced greater improvements with Fexuprazan use after 4 weeks, particularly in hoarseness and troublesome cough. No serious adverse events were reported. Thus, in the cohort of LPRD sufferers, Fexuprazan elicited remarkable improvements in symptoms and signs without any serious adverse events. Additionally, those with severe symptoms experienced a quicker alleviation with Fexuprazan compared to Esomeprazole.
European Archives of Oto-Rhino-Laryngology
Efficacy and safety of fexuprazan in patients with symptoms and signs of laryngopharyngeal reflux disease: a randomized clinical trial
Su Il Kim et al.
Comments (0)